FLUIDS iQ® is proud to offer the Preventis line of rapid, point-of-care tests specifically designed to aid the health care professional in differentiating between functional intestinal disease (eg: Irritable Bowel Syndrome\ IBS) and organic bowel disease (eg: Inflammatory Bowel Disease\IBD). These revolutionary tests, which deliver results in minutes, represent a new standard for helping the health care professional assess risk, preventing disease and enabling optimal treatment. They can be used in the health care professional's office, in the hospital or even by patients in their own home!


PreventID® CalDetect®  50/200*

PreventID® CalDetect® 50/200 is an immunological rapid test for the determination of faecal calprotectin. With two cut-offs at 50µg/g and 200 µg/g, this test not only helps the health care professional in assessing the differentiation of inflammatory (>50 µg/g) and non-inflammatory (>50 µg/g) diseases, but also IBD therapy monitoring, which remains a decision by the health care professional. A faecal calprotectin concentration above 200μg/g in drug treated IBD patients indicates a relapse. A periodic application of the PreventID® CalDetect® 50/200 in IBD patients is therefore an effective tool for the health care professional in providing individual therapy control.


*For Research Use Only (RUO)

For Patients - View the IBS\IBD Patient Brochure 

For Health Care Professionals - View the CalDetect® Manual 


Calprotectin – the key to differentiating between IBS and IBD

Calprotectin is present in the cytoplasm of neutrophils and plays a central role in immune defense. Upon neutrophil activation or endothelial adhesion of monocytes, Calprotectin is released and may be detected in serum, body fluids or stool as a potentially useful clinical inflammatory marker. The acute phase protein shows a high stability in faeces and has been established as a faecal marker of inflammatory bowel diseases (IBD). It allows a reliable differentiation between organic intestinal diseases (e.g. chronic inflammatory diseases, infectious diseases, polyps, colon cancer) and functional intestinal diseases (e.g. irritable bowel syndrome).

When to test for Calprotectin?
- To differentiate between IBS and IBD
- To differentiate between organic and functional diarrhoea
- To monitor disease activity in patients with IBD
-To check for early detection of relapse in IBD
- In patients with IBD symptoms, but normal c-reactive protein (CRP)
-  In children with suspected IBD, when a colonoscopy
is being considered


Read more about IBS\IBD and recent scientific literature pertaining to Calprotectin


• "Enzymes in feces: Useful markers of chronic inflammatory bowel disease"


• "Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial"


• "Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease"


• "Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease"


• "Role of Fecal Calprotectin as a Biomarker of Intestinal Inflammation in Inflammatory Bowel Disease"


• "The Utility of Biomarkers in the Diagnosis and Therapy of Inflammatory Bowel Disease"


• "Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome"


• "Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin"


• "Use of Surrogate Markers of Inflammation and Rome Criteria to Distinguish Organic From Nonorganic Intestinal Disease"


• "A simple method for assessing intestinal inflammation in Crohn’s disease"


• "Faecal calprotectin in colonic diverticular disease: a case–control study"


• "Diagnostic Precision of Fecal Calprotectin for Inflammatory Bowel Disease and Colorectal Malignancy"